33787-89-2

Upstream product

• 16532-79-9 4-Bromophenylacetonitrile 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 
• 68-12-2 N,N-dimethyl-formamide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 

Downstream Products

• 1248796-80-6 4-(4-bromophenyl)-1-methyl-1H-pyrazol-5-amine 
• 1404447-30-8 3-(4-bromophenyl)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 57999-08-3 3-amino-4-(4-bromophenyl)pyrazole 
• 1402465-79-5 (R)-1-phenylethyl 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazol-5-ylcarbamate 
• 1402465-78-4 1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-pyrazol-5-amine 
• 1402465-74-0 (R)-4-(4'-(1-methyl-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-4-yl)-[1,1'-biphenyl]-4-yl)-1-(methylsulfonyl)piperidine-4-carboxylic acid 
• 1402465-73-9 (R)-1-acetyl-4-(4'-(1-methyl-5-((1-phenylethoxy)carbonylamino)-1H-pyrazol-4-yl)biphenyl-4-yl)piperidine-4-carboxylic acid 
• 1402466-08-3 methyl 1-methyl-5-(4-(1-methyl-5-((((R)-1-phenylethoxy)carbonyl)amino)-1H-pyrazol-4-yl)phenyl)-2,3-dihydro-1H-indene-1-carboxylate 
• 1402465-20-6 (R)-3-(4'-(1-methyl-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-4-yl)-[1,1'-biphenyl]-4-yl)oxetane-3-carboxylic acid 
• 1359943-37-5 6-(4-bromophenyl)pyrazolo[1,5-a]pyrimidin-7-amine 

Relevant academic research and scientific papers

Application of vinylogous carbamates and vinylogous aminonitriles to the regiospecific synthesis of uniquely functionalized pyrroles and quinolones

Pyrroles and quinolones represent core structures, which are routinely found in both natural and synthetic bioactive substances. Consequently, the development of efficient and regiospecific methods for the preparation of such heterocycles with unique functionality is of some importance. We describe herein the regiospecific synthesis of 1,2,3,4-tetrasubstituted pyrroles containing polar substituents and such products are prepared from vinylogous carbamates and vinylogous aminonitriles. We also describe the regiospecific synthesis of 3-aryl containing 1,3,6-trisubstituted quinolones from vinylogous carbamates. The use of an amine exchange reaction to prepare precursors for the pyrrole and quinolone forming cyclizations represents a key factor in the strategy.

Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:Diacylglycerol acyltransferase 1

A high-throughput screen against human DGAT-1 led to the identification of a core structure that was subsequently optimized to afford the potent, selective, and orally bioavailable compound 14. Oral administration at doses ≥0.03 mg/kg significantly reduced postprandial triglycerides in mice following an oral lipid challenge. Further assessment in both acute and chronic safety pharmacology and toxicology studies demonstrated a clean profile up to high plasma levels, thus culminating in the nomination of 14 as clinical candidate ABT-046.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

COMPOSITIONS AND METHODS FOR MODULATING LPA RECEPTORS

The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).